[Illustrations] 2026 Obesity’s Second Wave: Market Fragmentation Starts to Challenge First-Generation Dominance

Within metabolic disease, 2026 is being positioned as the beginning of a “Second Wave” in the obesity supercycle, where the foundational dominance of Novo Nordisk and Eli Lilly is increasingly challenged by a cohort of innovators targeting the known limitations of first-generation injectable incretins. The central point is not that the existing category is losing relevance, but that a very large market is becoming more segmented as new products attempt to solve specific frictions.

These frictions are described as practical and persistent: the burden of administration for injectables, the tolerability ceilings created by gastrointestinal side effects, and concerns about incretin-induced muscle loss. As the market matures, investment attention is shifting from simply demonstrating powerful weight loss toward improving the experience and sustainability of treatment. The underlying economic premise is expansive: oral small molecule GLP-1 receptor agonists are framed as a key driver that could expand the total addressable market beyond $100 billion by 2030 by lowering barriers to adoption and enabling broader global access.

The fragmentation dynamic is also described as changing what “best” means. In the first wave, the headline metric was often peak weight loss over a defined period. In the second wave, differentiation is increasingly tied to which product patients can start more easily, tolerate more consistently, and stay on over time—factors that influence real-world outcomes and revenue durability. Convenience features are being elevated to strategic levers: oral formulations that avoid injections, less frequent dosing regimens that reduce adherence decay, and “incretin-plus” approaches that seek to preserve lean mass while maximizing fat loss. 

These shifts are being treated as more than incremental upgrades because they could broaden the treatable population and change reimbursement logic in some segments. In that sense, 2026 is depicted as a year when the obesity market’s next chapter is less about proving efficacy exists and more about proving which approaches can scale with fewer trade-offs in the daily lives of patients and the operational realities of healthcare systems.

Oral GLP-1s as an Access Strategy: Viking and Structure Move Toward Pivotal Tests

Among the most closely watched metabolic strategies is the move toward oral small molecule GLP-1 receptor agonists, positioned as a way to overcome logistical and psychological barriers associated with injectable therapies. The value proposition is framed in plain terms: pills fit existing routines and can reduce friction for patients who are hesitant about injections, potentially widening uptake and “democratizing” access, particularly at a global scale. 

Within this competitive set, Viking Therapeutics’ VK2735 is described as a dual GLP-1/GIP agonist where the differentiator is an oral tablet formulation that complements an injectable version already in Phase 3. The key 2026 catalyst is the initiation of, and potential interim data from, the pivotal Phase 3 program for the oral tablet. The central risk is also straightforward: gastrointestinal tolerability in larger populations, a recurring challenge for oral incretins that could shape persistence and commercial adoption even if efficacy remains strong.

Structure Therapeutics’ GSBR-1290 is described as approaching the same market with a mechanistic twist: a biased GPCR agonist platform designed to selectively activate G-protein signaling, a mechanism hypothesized to reduce severe nausea. In 2026, the initiation of its Phase 3 program—described as occurring in mid-2026—is framed as a binary validation event, not only for the asset but also for the platform’s tolerability thesis. A critical operational hurdle highlighted for Structure is the formulation bridge from capsule to commercial tablet, an area where the company has presented positive pharmacokinetic (PK) bridging data. 

Across both programs, the reporting emphasis remains on practical endpoints: not only how much weight is lost, but how manageable the side-effect profile is in broader patient populations and whether the final commercial form can maintain consistent exposure. In this framing, the “winner” in oral incretin is less the company that posts the most dramatic early efficacy and more the company that balances efficacy with tolerability and manufacturable formulation in a way that patients can live with for the long haul.

Roche’s CT-996 and the Push for Differentiated Positioning Beyond Weight Loss

Roche’s CT-996 is described as another once-daily oral GLP-1 agonist with an aggressive efficacy posture, but its strategic differentiation is framed less around convenience alone and more around clinical positioning—specifically, an emphasis on “normoglycemia induction” in pre-diabetic patients. The 2026 focal point is Phase 2 data readouts, which are portrayed as pivotal for clarifying both the efficacy profile and the plausibility of a distinct reimbursement pathway compared with therapies marketed primarily for weight loss. 

The rationale is that a prevention-oriented framing—centered on pre-diabetes and glycemic normalization—could align differently with payer decision-making than a pure obesity indication, potentially affecting adoption and coverage dynamics. At the same time, the reporting lens remains cautious: Phase 2 results can validate the direction of effect, but the durability of benefit and the tolerability profile in larger, more representative populations remain key variables that can alter the investment narrative.

The broader oral GLP-1 storyline is described as a balancing act in which the friction removed by avoiding injections may be reintroduced if daily dosing carries a persistent side-effect burden. In other words, oral delivery can expand the pool of willing starters, but real-world persistence becomes a central determinant of commercial impact. That is why gastrointestinal tolerability is repeatedly flagged as a defining risk for oral incretins. 

Another issue emphasized is the translational complexity of moving from early clinical formats to commercial products—particularly when bridging from capsule to tablet can introduce changes in absorption or exposure consistency. In this landscape, Phase 2 and Phase 3 milestones are portrayed as more than data points; they are operational proof-of-concept events. A therapy’s commercial viability is increasingly framed as dependent on whether it can deliver reliable efficacy with a tolerability profile that does not trigger high discontinuation rates, and whether the final formulation can be produced at scale without undermining the clinical profile that investors are underwriting.

Infrequent Dosing as a Moat: Amgen’s MariTide Targets the Maintenance Market

While oral GLP-1s are framed as a route to broaden initiation, a separate strategy is described as aiming directly at long-term persistence: infrequent dosing designed to capture the maintenance market. Amgen’s MariTide (maridebart cafraglutide) is presented as a leading example, with a mechanism combining a GLP-1 agonist and a GIP antagonist delivered via an antibody backbone that enables monthly or even quarterly subcutaneous administration. 

The strategic thesis is tied to patient adherence: less frequent dosing could reduce the “weekly injection fatigue” that can erode persistence over time, particularly in a chronic condition that often requires multi-year management. In this framing, dosing interval is treated as more than a convenience feature; it becomes a competitive lever that could influence long-term retention and, by extension, revenue durability. The maintenance segment is portrayed as especially important because a therapy’s lifetime value is heavily shaped by how many patients remain on treatment once early weight-loss momentum slows.

The primary 2026 risk highlighted for MariTide centers on the MARITIME Phase 3 program’s ability to manage the high rates of nausea and vomiting observed in Phase 2. The key variable described is the success of Amgen’s complex, multi-step dose titration protocol, which is positioned as the mechanism for improving tolerability while maintaining efficacy. In neutral terms, the reporting question becomes whether the protocol can function not only in controlled trial conditions but in ways that remain practical for real-world use, where complexity can itself become a barrier. 

If severe gastrointestinal side effects persist despite titration, discontinuation could undermine the intended adherence advantage of infrequent dosing. If titration meaningfully reduces severe events, the program could strengthen the case that extended half-life and less frequent administration are viable competitive moats. In the 2026 “clearing year” framing, the program is therefore described as a visible test of whether dosing convenience can be engineered without trading away tolerability, and whether operational complexity can be managed at scale.

Muscle Preservation Moves From Sidebar to Center Stage in Metabolic Competition

A notable shift described in the metabolic space is the growing focus on incretin-induced sarcopenia, or the loss of lean muscle mass, which can raise concerns about long-term frailty. As incretin therapies become more widely used, the reporting emphasis is expanding from “how much weight loss” to “what kind of weight loss,” with an emerging premium placed on “high-quality” outcomes that maximize fat loss while preserving muscle. This reframing carries both clinical and commercial implications: muscle loss can affect long-term function, and it can also shape patient satisfaction and persistence. 

In a market that is already crowded and highly competitive, differentiators that influence the lived experience of treatment—energy, strength, and functional capacity—can matter as much as peak weight-loss percentages. As a result, body composition metrics and fat-to-muscle loss ratios are described as becoming increasingly relevant in how programs may be evaluated and valued.

The leading strategy described for addressing this issue is the development of “incretin-plus” combinations, pairing a GLP-1 backbone with additional mechanisms intended to preserve or enhance lean mass, including approaches such as myostatin inhibition. Based on our research, it frames 2026 as a period when preliminary data quantifying fat-to-muscle loss ratios could arrive from companies such as Biohaven or Regeneron, readouts that could serve as early validation of the thesis and potentially set a new standard for efficacy in the field. 

Importantly, the reporting lens is not framed as assuming a particular outcome; rather, it presents these readouts as a measurement shift that could influence competitive positioning. If combinations demonstrate improved body composition outcomes without unacceptable new safety burdens, they could reshape expectations for what patients and clinicians consider an optimal therapy. If the combinations add complexity or side effects that reduce tolerability or adherence, they may face a different trade-off calculus. Either way, 2026 is presented as a year when muscle preservation moves closer to the core of metabolic drug competition, with data-driven comparisons increasingly likely to shape investor attention.

For our comprehensive topic on Investment Trends & Forecasts, please visit this link.

References: link.

Author

Oscar Wu

讓生醫資訊更加流通與透明化。